Baseline characteristics
| Cobra (n=81) | Cobra-light (n=83) | |
|---|---|---|
| Age, years | 53 (±13) | 51 (±13) |
| Women, n (%) | 54 (67%) | 58 (70%) |
| Disease duration (weeks) | 16 (9–28) | 17 (8–33) |
| RF positive, n (%) | 47 (58%) | 48 (58%) |
| Anti-CCP positive, n (%) | 50 (62%) | 55 (66%) |
| Erosive disease, n (%)* | 8 (10%) | 14 (17%) |
| DAS44 | 4.13 (±0.81) | 3.95 (±0.89) |
| DAS44 CRP | 3.98 (±0.73) | 3.83 (±0.85) |
| DAS28 | 5.67 (±1.13) | 5.45 (±1.29) |
| Tender joints | 17 (12–24) | 16 (10–23) |
| Swollen joints | 13 (10–17) | 11 (9–14) |
| Ritchie articular index | 10 (7–13) | 11 (7–13) |
| HAQ | 1.36 (±0.66) | 1.37 (±0.71) |
| ESR, mm/h | 27 (15–45) | 27 (12–48) |
| CRP, mg/l | 13 (5–27) | 13 (4–31) |
| Patient assessment disease activity, mm (0–100) | 64 (43–76) | 68 (52–84) |
| Patient assessment of pain, mm (0–100) | 64 (46–76) | 59 (38–78) |
| Patient global assessment, mm (0–100) | 62 (48–75) | 60 (36–78) |
| Physician assessment disease activity, mm (0–100) | 50 (40–60) | 46 (38–59) |
Data are expressed as mean (±SD) or median (IQR).
*Erosive disease according to the in-house radiologist.
Tender joints=53 joints, swollen joints=44 joints, Ritchie articular index=53 joints.
Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint disease activity score; DAS44, 44-joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; RF, rheumatoid factor.